文献速递脊柱关节炎

比美吉珠单抗治疗中轴型脊柱关节炎104周外周表现持续缓解

Sustained resolution of enthesitis and peripheral arthritis over 104 weeks with bimekizumab in axial spondyloarthritis.
PubMed 文献 · RMD Open · 2025-10-22

BE MOBILE 1(非放射学中轴型脊柱关节炎)与BE MOBILE 2(放射学中轴型脊柱关节炎)III期研究显示,比美吉珠单抗(BKZ)治疗至第104周时,附着点炎与周围关节炎持续改善;第104周超过40%的患者附着点炎消退(MASES=0),超过60%的患者关节炎消退(SJC=0)。

要点

  • 合并BKZ/安慰剂随机治疗者平均MASES由基线4.8/4.3降至第104周1.6/1.0(nr-axSpA/r-axSpA)。
  • 合并BKZ/安慰剂随机治疗者平均SJC由基线4.0/4.5降至第104周0.9/0.6(nr-axSpA/r-axSpA)。
  • 第104周超过40%患者附着点炎消退、超过60%患者关节炎消退。

核心结论

  • BKZ使中轴型脊柱关节炎全疾病谱患者的外周表现持续改善至2年。

研究设计与样本

  • BE MOBILE 1(nr-axSpA)与BE MOBILE 2(r-axSpA)III期研究:先16周双盲安慰剂对照,随后全部接受BKZ 160 mg每4周一次共36周,未达退出标准者可进入合并开放标签延伸期。
  • 分析基线MASES>0者的附着点炎变化、基线SJC>0者的周围关节炎(SJC/DAPSA)变化及至第104周达到DAPSA疾病状态的比例。
  • 报告基线有附着点炎/关节炎者至第104周的附着点炎消退(MASES=0)/关节炎消退(SJC=0),以及外周表现消退与第104周临床结局的关联。

主要发现

  • 基线时nr-axSpA患者中186/254(73.2%)有附着点炎(MASES>0)、88/254(34.6%)有关节炎(SJC>0);r-axSpA患者中分别为199/332(59.9%)和66/332(19.9%)。
  • 合并BKZ/安慰剂随机治疗的附着点炎患者(nr-axSpA/r-axSpA)平均MASES由基线4.8/4.3降至第52周1.6/1.3、第104周1.6/1.0。
  • 合并BKZ/安慰剂随机治疗的关节炎患者平均SJC由基线4.0/4.5降至第52周1.2/0.7、第104周0.9/0.6。
  • 超过60%的患者在第52周达到DAPSA低疾病活动度/缓解。
  • 第104周超过40%/60%的患者分别达到附着点炎消退(MASES=0)/关节炎消退(SJC=0);r-axSpA患者中附着点炎消退与第104周临床结局更大改善相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Bimekizumab (BKZ), a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F in addition to IL-17A, has demonstrated 2-year efficacy in non-radiographic axial spondyloarthritis (nr-axSpA) and radiographic axSpA (r-axSpA) phase III studies. OBJECTIVE: Assess the impact of BKZ on peripheral manifestations to week 104 of those studies. METHODS: BE MOBILE 1 (nr-axSpA) and 2 (r-axSpA) each comprised a 16-week double-blind, placebo-controlled period, then all received BKZ 160 mg every 4 weeks for 36 weeks. Patients not meeting withdrawal criteria could enter a combined open-label extension. We report change in enthesitis (Maastricht Ankylosing Spondylitis Enthesitis Score (MASES)) in patients with baseline MASES>0, peripheral arthritis (swollen joint count (SJC)/Disease Activity Index for Psoriatic Arthritis (DAPSA)) in patients with baseline SJC>0 and proportions achieving DAPSA disease states to week 104. Resolution of enthesitis (MASES=0)/arthritis (SJC=0) is reported to week 104 for those with baseline enthesitis/arthritis. We also report associations between peripheral manifestation resolution (MASES=0/SJC=0) and week 104 clinical outcomes in those with baseline enthesitis/arthritis. RESULTS: At baseline, 186/254 (73.2%) and 88/254 (34.6%) patients with nr-axSpA had enthesitis (MASES>0) and arthritis (SJC>0), respectively, compared with 199/332 (59.9%) and 66/332 (19.9%) patients with r-axSpA. Pooled BKZ/placebo-randomised patients with enthesitis (nr-axSpA/r-axSpA) showed average MASES improvement from 4.8/4.3 (baseline) to 1.6/1.3 (week 52) and 1.6/1.0 (week 104). Pooled BKZ/placebo-randomised patients with arthritis showed average SJC improvement from 4.0/4.5 (baseline) to 1.2/0.7 (week 52) and 0.9/0.6 (week 104). Over 60% of patients achieved DAPSA low disease activity/remission by week 52. Over 40%/60% patients achieved resolution of enthesitis (MASES=0)/arthritis (SJC=0) at week 104; enthesitis resolution was associated with larger improvements in week 104 clinical outcomes for patients with r-axSpA. CONCLUSION: BKZ resulted in sustained improvements in peripheral manifestations to 2 years across the full disease spectrum of axSpA.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Ramiro S, Poddubnyy D, Mease PJ, et al. Sustained resolution of enthesitis and peripheral arthritis over 104 weeks with bimekizumab in axial spondyloarthritis. RMD Open. 2025. PMID: 41125403. doi:10.1136/rmdopen-2025-005969

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。